Enliven Therapeutics Earnings Reports

Enliven Therapeutics reported a net loss of $28.5 million for the first quarter of 2025, an increase from the $22.7 million net loss in the same period last year. The company maintained a strong balance sheet with $289.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into late 2027. Key clinical updates include positive data from the ELVN-001 trial in CML and plans to explore strategic alternatives for the ELVN-002 program.

Enliven Therapeutics reported a net loss of $23.2 million for the fourth quarter of 2024, compared to a net loss of $19.4 million for the fourth quarter of 2023. The company maintains a strong cash position of $313.4 million, providing a cash runway into mid-2027.

Enliven Therapeutics reported its third quarter financial results, highlighting positive data from the Phase 1 clinical trial of ELVN-001 and continued progress with ELVN-002. The company's cash position remains strong with $291.8 million, expected to provide runway into late 2026.

Enliven Therapeutics reported its second quarter financial results, highlighting the dosing of the first patient in the Phase 1b arm of the ELVN-001 clinical trial and the first patient in the Phase 1a clinical trial of ELVN-002. The company's cash, cash equivalents, and marketable securities totaled $312.4 million, expected to provide cash runway into late 2026.

Enliven Therapeutics reported positive proof of concept data from the Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients. The company's cash, cash equivalents, and marketable securities totaled $320.5 million, which is expected to provide cash runway into late 2026.

Enliven Therapeutics reported a net loss of $19.4 million for the fourth quarter of 2023, with R&D expenses at $17.9 million and G&A expenses at $4.8 million. The company closed the year with $253.1 million in cash, cash equivalents, and marketable securities, expected to provide cash runway into early 2026. Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024.

Enliven Therapeutics reported its Q3 2023 financial results, highlighting progress in Phase 1 trials for ELVN-001 and ELVN-002, with initial proof of concept data expected in 2024. The company closed the quarter with $263.5 million in cash, cash equivalents, and marketable securities, expected to provide cash runway into early 2026.

Enliven Therapeutics reported a net loss of $16.7 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $277.9 million as of June 30, 2023. Patient enrollment and dose escalation continue to progress in the Phase 1 clinical trials of ELVN-001 and ELVN-002.

Enliven Therapeutics reported a net loss of $14.7 million for the first quarter of 2023. The company's cash and cash equivalents totaled $292.1 million as of March 31, 2023, expected to fund operations into early 2026.

Imara Inc. reported its full year 2021 financial results, highlighting the completion of enrollment in Phase 2b programs and the addition of a clinical indication in heart failure with preserved ejection fraction (HFpEF) for tovinontrine, along with the expansion of their pipeline to include IMR-261. The company's cash, cash equivalents and investments totaled $90.3 million. They anticipate that the cash will be sufficient to fund operations substantially through the first quarter of 2023.

Imara Inc. reported a net loss of $13.6 million for the third quarter of 2021. The company completed patient enrollment in Phase 2b clinical trials for tovinontrine in sickle cell disease and beta-thalassemia and expects to report interim analysis data in the fourth quarter of 2021. They also introduced a new pipeline program, IMR-261, for sickle cell disease.

Imara Inc. reported its second-quarter financial results, highlighting accelerated enrollment in Phase 2b trials for sickle cell disease and beta-thalassemia. The company also presented positive IMR-687 data and is developing a Phase 2 proof-of-concept study for HFpEF. A $50 million follow-on offering extends their cash runway through 2022.

Imara Inc. reported its financial results for the first quarter of 2021. They reported a net loss attributable to common stockholders of $10.3 million, or $0.58 per share. As of March 31, 2021, cash, cash equivalents and investments were $75.6 million.

Imara Inc. reported a net loss attributable to common stockholders of $49.2 million, or $3.53 per share, for the year ended December 31, 2020. The company's cash, cash equivalents, and investments totaled $88.2 million as of December 31, 2020. Research and development expenses were $32.2 million, and general and administrative expenses were $9.5 million for the year ended December 31, 2020.

Imara Inc. reported its third quarter 2020 financial results, highlighting the ongoing Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia, as well as the Orphan Drug designation granted by the European Commission for sickle cell disease.

Imara Inc. reported financial results for the second quarter ended June 30, 2020. The company's cash, cash equivalents and investments were $106.3 million. Research and development expenses were $7.9 million, and general and administrative expenses were $2.4 million. Net loss attributable to common stockholders was $10.2 million, or $0.59 per share.

Imara Inc. reported a net loss attributable to common stockholders of $15.1 million, or $4.31 per share, for the first quarter of 2020. The company's cash, cash equivalents and investments were $105.9 million as of March 31, 2020, and expects this, along with additional proceeds, will fund operations into mid-2022.